Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy

AIDS Research and Human Retroviruses

Volumn 23, Issue 12, 2007, Pages 1515-1520

  Kakehasi, Fabiana M ^a   Tupinambás, Unaí ^a   Cleto, Silvia ^a   Aleixo, Agdemir ^a   Lin, Elisa ^a   Melo, Victor H ^a   Aguiar, Regina A L P ^a   Pinto, Jorge A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; FEMALE; GENE MUTATION; GENOTYPE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; TREATMENT OUTCOME; VAGINAL DELIVERY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MUTATION; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD; ZIDOVUDINE;

EID: 37549057650     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0025     Document Type: Article

References (41)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180.
2. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabitto C, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET012 randomized trial. Lancet 1999;354:795-802.
3. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart, et al.: DITRAME Study Group. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-792.
4. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al.: Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial. Lancet 1999;353:773-780.
5. Whiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin AT, et al.: Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: A randomized controlled trial. Lancet 1999;353:781-785.
6. Dorenbaum A, Cunnigngham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al.: Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. JAMA 2002;288:189-198.
7. Moodley D, Moodley J, Coovadia H, Gray G, McIntrye J, Hofmer J, et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-735.
8. ANRS 1201/1202 DITRAME PLUS Study Group: Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005;19:309-318.
9. Ministério da Saude, Secretaria de Vigilancia em Saude, Brasil: Programa Nacional de DST e Aids. Recomendações para a profilaxia da transmissão materno-infantil do HIV e terapia anti-retroviral em gestantes. Available at www.aids.gov.br.
10. Eastman DE, Coombs RW, Frenkel LM, McSherry GD, Britto P, Herman SA, et al.: Maternal viral load genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:577-563.
11. Kully C, Yerly S, Erb P, Kind C, Krautheim A, Perrin L, et al.: Codon 215 mutations in human immunodeficiency virus-infected women. J Infect Dis 1999;179:705-708.
12. Welles SJ, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, et al.: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000;14:263-271.
13. Ekpini RA, Nkengsong JN, Sibailly T, Maurice C, Adjé C, Monga BB, et al.: Changes in plasma HIV-1 RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002;16:625-630.
14. Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003;32:170-181
15. Bauer GR, Welles SL, Colgrove RR, and Pitt J: Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission of zidovudine monotherapy-treated women with moderately advanced disease. J Acquir Immune Defic Syndr 2003;34:312-319.
16. Larbalestier N, Mullen J, O'Shea S, Cottam F, Sabin CA, Chrystie IL, et al.: Drug resistance is uncommon in pregnant women with low viral load taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS 2003;17:2667-2671.
17. Clarke JR, Braganza R, Mirza A, Stainsby S, Ait-Khaled M, Wright A, et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999;59:364-368.
18. Mandelbrot L, Mascaro AL, Rekacewicz C, Berrebi A, Bénifla JL, Burgard M, et al.: Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-2093.
19. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler G, et al.: Identification of the K103N resistance mutation in Uganda women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14:F111-F115.
20. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunnigham S, Mirochnick M, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET012). AIDS 2001;15:1951-1957.
21. Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al.: Development resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediactrics AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002;186:181-188.
22. Jourdain G, Houng NNG, Le Couer S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;335:229-240.
23. Eshleman SH, Guay L, Mwatha A, Brown ER, Cunningham SP, Musoke P, et al.: Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET012). J Acquir Immune Defic Syndr 2004;35:126-130.
24. Eshelman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005;192:30-35.
25. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, and Mulcahy FM: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005;19:63-67.
26. Overton ET, Sungkanuparph S, Nurutdinova D, and Powderly WG: Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. AIDS 2005;19:1439-1442.
27. Perez H, Vignoles M, Laufer N, Schvacha N, Dolcini G, Coll P, et al.: Post-partum interruption of a triple drug regimen containing nevirapine for prevention of mother-to-child transmission does not select the K103N mutation [abstract]. Proceedings of the 13th Conference on Retrovirus and Opportunistic Infections, Denver, CO, February 5-8, 2006.
28. Centers for Disease Control and Prevention: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR17).
29. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pilay D, et al.: Update of the drug resistance mutation in HIV-1: 2005. Top HIV Med 2005;13(1):51-57.
30. Kumar S, Tamura K, and Nei M: MEGA: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004;5:150-163.
31. Nellen JFJB, Schillevort I, Wit FWNM, Bergshoeff AS, Godfried MH, Boer K, et al.: Nelfinavir plasma concentration are low during pregnancy. Clin Infect Dis 2004;39:736-740.
32. Khuong-Jones MA, Boussairi A, Herida M, Abbas S, and Méchali D: Nelfinavir plasma concentration in 40 pregnant women. [abstract]. Proceedings of the 13th Conference on Retrovirus and Opportunistic Infections, Denver, CO, February 5-8, 2006.
33. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, et al.: Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006;62;3:309-315.
34. Perez EE, Rose SL, Peyser B, Lamers SL, Burkhardt B, Dunn BM, et al.: Human immunodeficiency virus type I protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PI) in PI-naïve patients. J Infect Dis 2001;183:579-588.
35. Kanto R, Katzenstein T. Drug resistance in non-subtype B HIV-1. J Clin Virol 2004;29:152-159.
36. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, and Peeters M: Natural polymorphism in protease and reverse transcriptase genes and in antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naïve patients. J Clin Virol 2006;36:43-49.
37. Dumans AT, Soares MA, Pieniazek D, Kalish ML, Vroey V, Hertogs K, et al.: Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother 2002;46:3075-3079.
38. Soares MA, Brindeiro RM, and Tanuri A: Primary HIV-1 drug resistance in Brazil. AIDS 2004;18(Suppl. 3):S9-S13.
39. Devereux HL, Youle M, Johnson MA, and Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-F127.
40. Balduin M, Sierra S, Daumer MP, Rockstroh JK, Oette M, Fatkenheuer G, et al.: Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol 2005;34:277-287.
41. Little SJ, Koelsch KK, Ignacio CC, Wong JK, Lie Y, Frost SDW, et al.: Persistance of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy [abstract]. Proceedings of the 11th Conference on Retrovirus and Opportunistic Infections, San Francisco, CA, February 8-11, 2004.